RxDoctor Payments Data

Jessica Wachtel, MD

Internal Medicine · West Orange, NJNPI 1396011573

Payments from drug & device makers

$4,379in general payments, 2019–2025

Across 184 payments — averaging $23.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$843
  • Novo Nordisk$652
  • Amgen$610
  • AstraZeneca$396
  • AbbVie$269
  • Lilly USA, LLC$257
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$4,379100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,379 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$44,962
Medicare patients
152
Services billed
388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$49,132
JardianceEmpagliflozin29$34,167
TrulicityDulaglutide12$15,874
MyrbetriqMirabegron17$12,396
EliquisApixaban14$10,291
Sevelamer Carbonate13$6,550
Atorvastatin Calcium147$1,558
Clonidine12$1,523
Albuterol Sulfate HfaAlbuterol Sulfate33$994
Amlodipine Besylate111$619
Valsartan17$572
Fluticasone Propionate27$473
Pantoprazole Sodium28$393
Losartan Potassium48$386
Metformin Hcl ErMetformin Hcl14$377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$652$49,13234 claims
Boehringer IngelheimJardiance$843$34,16729 claims
Lilly USA, LLCTrulicity$257$15,87412 claims
PfizerEliquis$226$10,29114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in West Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →